Chen Liang, Gao Guo-Ming, Li Dong-Lu, Chen Zhong-Ke
Department of Interventional Therapy, Tianshui Second People's Hospital, Tianshui, China.
Department of Anatomy, Gansu Medical College, Pingliang, China.
Wideochir Inne Tech Maloinwazyjne. 2022 Jun;17(2):279-288. doi: 10.5114/wiitm.2021.112477. Epub 2022 Jan 9.
Both side-by-side (SBS) and stent-in-stent (SIS) bilateral stenting have been used for patients with malignant hilar biliary obstruction (MHBO). However, it is unclear which technique is better.
This meta-analysis is conducted to investigate the clinical efficacy and safety of SBS and SIS bilateral stenting for patients with MHBO.
Relevant studies were searched in PubMed, Embase, Cochrane Library, Wanfang, VIP, and CINK databases. The timeline for the searches was from the establishment of the database to September 2021. The relative outcomes are pooled.
A total of 7 studies fulfilled the inclusion criteria and entered into this meta-analysis. The pooled technical success rate was significant higher in the SIS group than that in the SBS group (p = 0.04). The pooled early complication rate was significantly lower in the SIS group than in the SBS group (p = 0.04). The pooled stent re-obstruction rate was significantly lower in the SBS group than in the SIS group (p = 0.04). The pooled stent patency duration was significantly longer in the SBS group than in the SIS group (p = 0.01). The pooled functional success rates (p = 0.79), total complication rates (p = 0.34), and overall survival duration (p = 0.27) were comparable between 2 groups. Egger test did not show any publication bias.
When comparing the SBS and SIS bilateral stenting for patients with MHBO, although SIS technique may have the superiorities of technical success and early complication rates, the longer stent patency was achieved by the SBS technique.
并排(SBS)双侧支架置入术和支架内支架(SIS)双侧支架置入术均已用于治疗恶性肝门部胆管梗阻(MHBO)患者。然而,尚不清楚哪种技术更好。
本荟萃分析旨在探讨SBS和SIS双侧支架置入术治疗MHBO患者的临床疗效和安全性。
在PubMed、Embase、Cochrane图书馆、万方、维普和中国知网数据库中检索相关研究。检索时间范围为各数据库建立至2021年9月。汇总相关结果。
共有7项研究符合纳入标准并纳入本荟萃分析。SIS组的汇总技术成功率显著高于SBS组(p = 0.04)。SIS组的汇总早期并发症发生率显著低于SBS组(p = 0.04)。SBS组的汇总支架再梗阻率显著低于SIS组(p = 0.04)。SBS组的汇总支架通畅持续时间显著长于SIS组(p = 0.01)。两组之间的汇总功能成功率(p = 0.79)、总并发症发生率(p = 0.34)和总生存时间(p = 0.27)相当。Egger检验未显示任何发表偏倚。
在比较SBS和SIS双侧支架置入术治疗MHBO患者时,虽然SIS技术在技术成功率和早期并发症发生率方面可能具有优势,但SBS技术可实现更长的支架通畅时间。